Amicus Therapeutics (FOLD) 2.13 $FOLD
Amicus Therapeutics Announces First Quarter 2014 Financial Results and Corporate Updates
GlobeNewswire - Mon May 05, 3:00PM CDT
Positive 12- and 24-Month Data From First Phase 3 Fabry Monotherapy Study (Study 011) - Results from Second Phase 3 Fabry Monotherapy Study (Study 012) Expected 3Q14
Dr. Farzad Mostashari to keynote SAS Health Analytics Executive Conference
Business Wire - Mon May 05, 9:29AM CDT
11th Annual SAS Health Analytics Executive Conference--Analytics is increasingly indispensable as the health care industry moves toward greater transparency. To address the latest efforts to improve data transparency, care delivery and consumer engagement, more than 300 thought leaders will convene at the 11th Annual SAS Health Analytics Executive Conference in Cary, NC, on May 14.
Positive Data, Financial Results, and Drug Development Programs - Analyst Notes on Novavax, Ironwood, XOMA, Luminex and Amicus
PR Newswire - Fri May 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Novavax, Inc. (NASDAQ: NVAX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), XOMA Corporation (NASDAQ: XOMA), Luminex Corporation (NASDAQ: LMNX) and Amicus Therapeutics, Inc. (NASDAQ: FOLD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1940-100free.
Amicus Therapeutics to Announce First Quarter 2014
GlobeNewswire - Thu May 01, 9:40AM CDT
Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Monday, May 5, 2014 at 5:00 p.m. ET to discuss financial results for the first quarter ended March 31, 2014.
Amicus Up on Positive Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 1:32PM CDT
Shares of Amicus Therapeutics (FOLD) shot up 20.7% after it announced positive data from its first phase III study on migalastat HCl monotherapy.
Amicus Therapeutics (FOLD) Jumps: Stock Up 20.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 8:39AM CDT
Amicus Therapeutics, Inc. (FOLD) was a big mover last session, as its shares rose nearly 21% on the day.
Morning Review on Top Gainers -- Research on Banco Santander Brasil, Novavax, Cadence Design Systems, and Amicus Therapeutics
PR Newswire - Wed Apr 30, 7:00AM CDT
The US markets saw a positive sentiment on Tuesday, April 29, 2014, with the NASDAQ Composite closing at 4,103.54, up 0.72%, the Dow Jones Industrial Average ending the session 0.53% higher at 16,535.37, and the S&P 500 edging 0.48% higher to finish the trading session at 1,878.33. During the session gains in the Financials, Information Technology and Materials sectors positively impacted the broader market, while some retraction came in from Utilities and Consumer Staples sectors. A number of stocks saw large movements, including Banco Santander Brasil S.A. (NYSE: BSBR), Novavax Inc. (NASDAQ: NVAX), Cadence Design Systems Inc. (NASDAQ: CDNS) and Amicus Therapeutics Inc. (NASDAQ: FOLD). Free technical research on BSBR, NVAX, CDNS and FOLD can be downloaded upon signing up at:
Massive Swings: Biota Pharmaceuticals, Inc. and Amicus Therapeutics, Inc.
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
Healthcare investors were presented with major movements in two small stocks today: Amicus Therapeutics popped almost 21% on strong phase 3 data for a Fabry disease drug, while Biota Pharmaceuticals collapsed 34% upon receiving a stop-work...
Why Amicus Therapuetics (FOLD) Stock Is Surging Today
at The Street - Tue Apr 29, 1:18PM CDT
Amicus Therapuetics (FOLD) surged Tuesday after the company announced its fat-storage disorder drug migalastat was effective in treating patients with Fabry disease in a late-stage trial.
Hot Stock: Amicus Therapeutics, Shares Gain 25.5% (FOLD)
Comtex SmarTrend(R) - Tue Apr 29, 10:10AM CDT
Amicus Therapeutics (NASDAQ:FOLD) is one of today's best performing low-priced stocks, up 25.5% to $2.31 on 8.6x average daily volume. Thus far today, Amicus Therapeutics has traded 3.6 million shares, vs. average volume of 421,000 shares per day. The stock has outperformed the Dow (25.5% to the Dow's 0.5%) and outperformed the S&P 500 (25.5% to the S&P's 0.3%) during today's trading.
Amicus Therapeutics (FOLD) Crumbles: Stock Falls by 8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 7:33AM CDT
Amicus has not seen any positive earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
Hot Stock: Amicus Therapeutics, Shares Drop 9.0% (FOLD)
Comtex SmarTrend(R) - Tue Apr 15, 10:11AM CDT
Amicus Therapeutics (NASDAQ:FOLD) is one of today's worst performing low-priced stocks, down 9.0% to $1.82 on 4.5x average daily volume. Thus far today, Amicus Therapeutics has traded 1.2 million shares, vs. average volume of 263,000 shares per day. The stock has underperformed the Dow (-9.0% to the Dow's -0.1%) and underperformed the S&P 500 (-9.0% to the S&P's -0.1%) during today's trading.
Amicus Therapeutics to Present at 13th Annual Needham Healthcare Conference
GlobeNewswire - Thu Mar 27, 3:39PM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the 13th Annual Needham Healthcare Conference on Wednesday, April 9, 2014 at 3:40 p.m. ET.
Zacks Rank #5 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (strong sell) List for Tuesday
Amicus Therapeutics Announces Full-Year 2013 Financial Results and Corporate Updates
GlobeNewswire - Mon Mar 03, 3:01PM CST
Executing 3-in-3 Strategy to Advance 3 Next-Generation ERTs into Clinic in Next 3 Years
Amicus Therapeutics Appoints Jay A. Barth, MD as Chief Medical Officer and Promotes Bradley L. Campbell to Chief Operating Officer
GlobeNewswire - Mon Mar 03, 6:30AM CST
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced the appointment of Jay A. Barth, MD as Chief Medical Officer, effective today. Dr. Barth brings to Amicus more than 15 years of experience in drug development, clinical research and medical affairs. In his role as Chief Medical Officer, he will be responsible for all clinical development activities as well as regulatory affairs. The Company also announced the promotion of Bradley L. Campbell from Chief Business Officer to Chief Operating Officer, effective December 2013. Both Dr. Barth and Mr. Campbell report to John F. Crowley, Chairman and Chief Executive Officer of Amicus.
Amicus Therapeutics to Present at Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Thu Feb 27, 9:12AM CST
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the Cowen and Company 34 Annual Health Care Conference on Tuesday, March 4, 2014 at 10:00 a.m. ET.
Amicus Therapeutics, Inc. [FOLD] to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Thu Feb 27, 9:00AM CST
What:
Amicus Therapeutics to Announce Full-Year 2013 Financial Results on March 3, 2014
GlobeNewswire - Wed Feb 26, 8:51AM CST
Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Monday, March 3, 2014 at 5:00 p.m. ET to discuss financial results for the full year ended December 31, 2013.
Amicus Therapeutics Highlights Data Featured at Lysosomal Disease Network WORLD Symposium 2014
GlobeNewswire - Wed Feb 12, 6:30AM CST
First Scientific Meeting to Present Preclinical Proof-of-Concept Data for Next-Generation Pompe ERT and Proprietary Enzyme Targeting Technology
Amicus Therapeutics Announces First Quarter 2014 Financial Results and Corporate Updates
GlobeNewswire - Mon May 05, 3:00PM CDT
Positive 12- and 24-Month Data From First Phase 3 Fabry Monotherapy Study (Study 011) - Results from Second Phase 3 Fabry Monotherapy Study (Study 012) Expected 3Q14
Dr. Farzad Mostashari to keynote SAS Health Analytics Executive Conference
Business Wire - Mon May 05, 9:29AM CDT
11th Annual SAS Health Analytics Executive Conference--Analytics is increasingly indispensable as the health care industry moves toward greater transparency. To address the latest efforts to improve data transparency, care delivery and consumer engagement, more than 300 thought leaders will convene at the 11th Annual SAS Health Analytics Executive Conference in Cary, NC, on May 14.
Positive Data, Financial Results, and Drug Development Programs - Analyst Notes on Novavax, Ironwood, XOMA, Luminex and Amicus
PR Newswire - Fri May 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Novavax, Inc. (NASDAQ: NVAX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), XOMA Corporation (NASDAQ: XOMA), Luminex Corporation (NASDAQ: LMNX) and Amicus Therapeutics, Inc. (NASDAQ: FOLD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1940-100free.
Amicus Therapeutics to Announce First Quarter 2014
GlobeNewswire - Thu May 01, 9:40AM CDT
Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Monday, May 5, 2014 at 5:00 p.m. ET to discuss financial results for the first quarter ended March 31, 2014.
Amicus Up on Positive Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 1:32PM CDT
Shares of Amicus Therapeutics (FOLD) shot up 20.7% after it announced positive data from its first phase III study on migalastat HCl monotherapy.
Amicus Therapeutics (FOLD) Jumps: Stock Up 20.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 8:39AM CDT
Amicus Therapeutics, Inc. (FOLD) was a big mover last session, as its shares rose nearly 21% on the day.
Morning Review on Top Gainers -- Research on Banco Santander Brasil, Novavax, Cadence Design Systems, and Amicus Therapeutics
PR Newswire - Wed Apr 30, 7:00AM CDT
The US markets saw a positive sentiment on Tuesday, April 29, 2014, with the NASDAQ Composite closing at 4,103.54, up 0.72%, the Dow Jones Industrial Average ending the session 0.53% higher at 16,535.37, and the S&P 500 edging 0.48% higher to finish the trading session at 1,878.33. During the session gains in the Financials, Information Technology and Materials sectors positively impacted the broader market, while some retraction came in from Utilities and Consumer Staples sectors. A number of stocks saw large movements, including Banco Santander Brasil S.A. (NYSE: BSBR), Novavax Inc. (NASDAQ: NVAX), Cadence Design Systems Inc. (NASDAQ: CDNS) and Amicus Therapeutics Inc. (NASDAQ: FOLD). Free technical research on BSBR, NVAX, CDNS and FOLD can be downloaded upon signing up at:
Massive Swings: Biota Pharmaceuticals, Inc. and Amicus Therapeutics, Inc.
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
Healthcare investors were presented with major movements in two small stocks today: Amicus Therapeutics popped almost 21% on strong phase 3 data for a Fabry disease drug, while Biota Pharmaceuticals collapsed 34% upon receiving a stop-work...
Why Amicus Therapuetics (FOLD) Stock Is Surging Today
at The Street - Tue Apr 29, 1:18PM CDT
Amicus Therapuetics (FOLD) surged Tuesday after the company announced its fat-storage disorder drug migalastat was effective in treating patients with Fabry disease in a late-stage trial.
Hot Stock: Amicus Therapeutics, Shares Gain 25.5% (FOLD)
Comtex SmarTrend(R) - Tue Apr 29, 10:10AM CDT
Amicus Therapeutics (NASDAQ:FOLD) is one of today's best performing low-priced stocks, up 25.5% to $2.31 on 8.6x average daily volume. Thus far today, Amicus Therapeutics has traded 3.6 million shares, vs. average volume of 421,000 shares per day. The stock has outperformed the Dow (25.5% to the Dow's 0.5%) and outperformed the S&P 500 (25.5% to the S&P's 0.3%) during today's trading.
Amicus Therapeutics (FOLD) Crumbles: Stock Falls by 8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 7:33AM CDT
Amicus has not seen any positive earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
Hot Stock: Amicus Therapeutics, Shares Drop 9.0% (FOLD)
Comtex SmarTrend(R) - Tue Apr 15, 10:11AM CDT
Amicus Therapeutics (NASDAQ:FOLD) is one of today's worst performing low-priced stocks, down 9.0% to $1.82 on 4.5x average daily volume. Thus far today, Amicus Therapeutics has traded 1.2 million shares, vs. average volume of 263,000 shares per day. The stock has underperformed the Dow (-9.0% to the Dow's -0.1%) and underperformed the S&P 500 (-9.0% to the S&P's -0.1%) during today's trading.
Amicus Therapeutics to Present at 13th Annual Needham Healthcare Conference
GlobeNewswire - Thu Mar 27, 3:39PM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the 13th Annual Needham Healthcare Conference on Wednesday, April 9, 2014 at 3:40 p.m. ET.
Zacks Rank #5 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (strong sell) List for Tuesday
Amicus Therapeutics Announces Full-Year 2013 Financial Results and Corporate Updates
GlobeNewswire - Mon Mar 03, 3:01PM CST
Executing 3-in-3 Strategy to Advance 3 Next-Generation ERTs into Clinic in Next 3 Years
Amicus Therapeutics Appoints Jay A. Barth, MD as Chief Medical Officer and Promotes Bradley L. Campbell to Chief Operating Officer
GlobeNewswire - Mon Mar 03, 6:30AM CST
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced the appointment of Jay A. Barth, MD as Chief Medical Officer, effective today. Dr. Barth brings to Amicus more than 15 years of experience in drug development, clinical research and medical affairs. In his role as Chief Medical Officer, he will be responsible for all clinical development activities as well as regulatory affairs. The Company also announced the promotion of Bradley L. Campbell from Chief Business Officer to Chief Operating Officer, effective December 2013. Both Dr. Barth and Mr. Campbell report to John F. Crowley, Chairman and Chief Executive Officer of Amicus.
Amicus Therapeutics to Present at Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Thu Feb 27, 9:12AM CST
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the Cowen and Company 34 Annual Health Care Conference on Tuesday, March 4, 2014 at 10:00 a.m. ET.
Amicus Therapeutics, Inc. [FOLD] to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Thu Feb 27, 9:00AM CST
What:
Amicus Therapeutics to Announce Full-Year 2013 Financial Results on March 3, 2014
GlobeNewswire - Wed Feb 26, 8:51AM CST
Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Monday, March 3, 2014 at 5:00 p.m. ET to discuss financial results for the full year ended December 31, 2013.
Amicus Therapeutics Highlights Data Featured at Lysosomal Disease Network WORLD Symposium 2014
GlobeNewswire - Wed Feb 12, 6:30AM CST
First Scientific Meeting to Present Preclinical Proof-of-Concept Data for Next-Generation Pompe ERT and Proprietary Enzyme Targeting Technology
